7.54 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||7.52 x 1000|
|Ask||7.53 x 800|
|Day's Range||7.41 - 7.80|
|52 Week Range||6.04 - 23.83|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 13, 2019 - Aug 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.10|
Half of the 34 businesses from the region that debuted on Wall Street in 2018 are now trading below their initial offering price, and three have experienced bigger percentage drops than Bloom.
Forty Seven Inc. (FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today reported financial results for the second quarter ended June 30, 2019 and provided a business update.
Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced additional funding commitments from The Leukemia & Lymphoma Society (LLS), aimed at accelerating the development of 5F9 for the treatment of myelodysplastic syndromes (MDS). Forty Seven presented updated initial data from its Phase 1b clinical study of 5F9 in patients with MDS at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, IL and 2019 European Hematology Association Annual Meeting in Amsterdam, Netherlands in June 2019, showing an overall response rate (ORR) of 100% and a complete response (CR) rate of 55% among patients treated with 5F9 in combination with azacitidine.
MENLO PARK, Calif., July 31, 2019 -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the.
Biotech stocks can make compelling investments if investors can pick the right ones. One way to find these winners is to look at the stocks corporate insiders are buying. While an investment decision shouldn’t be made solely on the basis of insider activity, it is an important factor to consider. We are taking a closer look at 3 biotech stocks showing positive insider signals. AVROBIO, Inc. (AVRO)AVRO is a phase 2 clinical-stage gene therapy company that develops treatments for rare diseases such as Fabry Disease, a lysosomal disease that affects the kidneys, heart and skin. Following the announcement on July 19 that it closed its underwritten public offering of 7,475,000 shares of common stock, both the director, Bruce Booth, and Atlas Venture Fund X, L.P. bought over $15 million worth of the stock. Each bought 810,811 shares at an average price of $18.50 per share, with both becoming 24% owners. AVRO plans to use the money generated from the offering for its current Fabry Disease, Gaucher Disease, Cystinosis and Pompe Disease programs as well as to fund further research and development. The purchase comes after top analyst, Difei Yang, reiterated her Buy rating and $28 price target on July 16, suggesting 25% upside. The Mizuho Securities analyst said “AVROBIO has a $4.0 billion total addressable market (TAM). Available clinical data in Fabry disease has shown encouraging results with initial patients treated achieving meaningful improvements in enzyme activity levels and two patients discontinuing enzyme replacement therapy so far (the standard of care).”Another analyst, Debjit Chattopadhyay, also reiterated his Buy rating and $40 price target on July 16. He believes AVRO could soar by as much as 78% over the next twelve months. “While our price target reflects uncertainties stemming from the clinical update from the Fabry program (AVR-RD-01), resulting in: (1) a push out of our launch estimate into 2H-2022, vs. prior 2H-2021; and (2) lower Fabry POS of 25% from 30%, we believe the company is still poised for substantial long-term growth,” the H.C. Wainwright analyst said. The Street is also bullish on AVRO. The stock boasts a ‘Strong Buy’ analyst consensus and $34 average price target, indicating 51% upside potential.Esperion Therapeutics, Inc. (ESPR)ESPR specializes in developing lipid management treatments for patients with high cholesterol. On July 23, BIOTECH TARGET N V, bought 50,000 shares at an average price of $42.65 per share, bringing the total purchase price to over $2 million. This makes Biotech Target a 13% owner of the company.The buy comes after ESPR announced that it entered into a $200 million funding agreement with Oberland Capital on June 26. The agreement is based on net revenues from ESPR’s bempedoic acid and the bempedoic acid/ezetimibe combination tablet sales with $125 million given upfront, $25 million upon FDA approval and $50 million at Esperion’s option after launch.Cowen & Co. analyst, Chris Shibutani, argues that this funding will drive continued growth. On July 18, he maintained his Buy rating and $80 price target. He believes share prices could surge by as much as 92% over the next twelve months. On June 27, analyst, Michael Yee, said, “Esperion's debt financing brings in an immediate $125M, lifting the company's total pro-forma cash to $355M, and gives it flexibility going into 2020\. We view the deal as a non-dilutive, fundamentally good access to cash, that helps shore up Esperion's balance sheet in case of uncertainty and macro risk in 2020.” The Jefferies analyst maintained his Buy rating and $85 price target, suggesting 104% upside potential. ESPR has a ‘Moderate Buy’ analyst consensus, and $85 average price target, indicating 103% upside.Forty Seven, Inc. (FTSV)On July 22, both FTSV’s director, Jeffrey W. Bird, and Lightspeed Venture Partners X, L.P. increased their stakes in the cancer-fighting biotech company formerly known as CD47 Sciences, Inc. Bird purchased 750,000 shares for $6 million while Lightspeed bought 625,000 shares for $5 million at an average price of $8 per share.The purchase fell on the same day as the company’s announcement that it closed its public offering of 10,781,250 shares. The offering included 1,406,250 shares that could be bought by the underwriters. The buy also occurred shortly after news broke of its license agreement with Ono Pharmaceutical. On July 11, it was announced that FTSV would get the exclusive right to develop, manufacture and commercialize the 5F9 monoclonal antibody that targets CD47, a protein that can cause tumors. Analyst Swayampakula Ramakanth believes the licensing agreement could drive share price growth of 130% over the next twelve months. The H.C. Wainwright analyst maintained a Buy rating and $21 price target on July 12. “We derive our price target based on a risk-based NPV (rNPV) analysis of projected 5F9 revenues through 2030 assuming a 12% discount rate and a 3% terminal growth rate. We derive rNPV of $1.1B for 5F9 and add in cash, cash equivalents, and short-term investments of $114M to arrive at a 12-month price target of $20.57 per diluted share, which we round to $21.00,” Ramakanth added. JonesTrading analyst, Soumit Roy, reiterated his Buy rating and $30 price target on June 14. He believes share prices could jump by an impressive 228% over the next twelve months. “We think share prices are going to recover following the success of the company’s anti-PD(L)-1 drugs,” he said. FTSV has a ‘Strong Buy’ analyst consensus and $26 average price target, suggesting 188% upside potential.
MENLO PARK, Calif., July 22, 2019 -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public.
MENLO PARK, Calif., July 17, 2019 -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced.
Forty Seven, Inc. (FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares of common stock are being offered by Forty Seven. In connection with this offering, Forty Seven expects to grant the underwriters a 30-day option to purchase up to $11,250,000 of additional shares of common stock.
Forty Seven (NASDAQ: FTSV ) and Ono Pharmaceutical have inked an exclusive license agreement for the development, manufacture and commercialization of 5F9, Forty Seven’s monoclonal antibody against CD47. ...
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, and Ono Pharmaceutical Co., Ltd. today announced an exclusive license agreement for the development, manufacture and commercialization of 5F9, Forty Seven’s monoclonal antibody against CD47. The agreement includes all therapeutic uses of 5F9 as a monotherapy or combination agent in Japan, South Korea, Taiwan and the ASEAN countries (the “Territory”). Under the terms of the agreement, Forty Seven will receive a one-time upfront payment of approximately $15.8 million from Ono.
Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced updated data from its ongoing Phase 1b/2 clinical trial evaluating 5F9 in combination with rituximab for the treatment of relapsed/refractory non-Hodgkin’s lymphoma (r/r NHL), including diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma. The data will be presented in an oral session at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, Netherlands.
Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced updated initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The data, which have matured since the abstract submission and now include additional patients and longer-term follow-up, will be presented in a poster discussion session at the 2019 ASCO Annual Meeting in Chicago, Illinois.
MENLO PARK, Calif., May 16, 2019 -- Forty Seven, Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against.
-- Forty Seven to Host Investor Event and Webcast on June 3, 2019 ---- Forty Seven Management to Participate in MATTER Panel, The Current and Future Wave of Immuno-Oncology.
Forty Seven Inc. (FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today reported financial results for the first quarter ended March 31, 2019 and provided a business update. “Our achievements year-to-date reflect our commitment to maximizing the potential of 5F9 as a novel, first-in-class therapeutic for the treatment of cancer,” said Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of Forty Seven, Inc. “Building on the promising results observed in our Phase 1b NHL trial, we recently entered into additional clinical collaborations to evaluate 5F9 as part of two triplet regimens for patients with the most aggressive forms of the disease.
NEW YORK, NY / ACCESSWIRE / May 13, 2019 / Forty Seven, Inc. (NASDAQ: FTSV ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 13, 2019 at 4:30 PM Eastern ...
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
MENLO PARK, Calif., May 06, 2019 -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the.
Forty Seven Inc. (FTSV), a clinical-stage company immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced an extension of its agreement with Genentech, a member of the Roche Group. Under the terms of the extension, the companies will initiate a third clinical trial, evaluating Forty Seven’s CD47 antibody 5F9 in combination with Genentech’s anti-CD20 antibody rituximab (Rituxan®) and anti-PDL1 antibody, atezolizumab (Tecentriq®), in patients with diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin’s lymphoma (NHL).
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The big shareholder groups in Forty Seven, Inc. (NASDAQ:FTSV) have power over the company. Institutions will often hold...